Mingxi Lin

Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026

Correction: Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer.

Correction: Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer.

Journal: Genes and immunity
Published: February 10, 2026

AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies.

AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies.

Journal: Oncogene
Published: February 02, 2026

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade.

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 28, 2025

Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases.

Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases.

Journal: Nature communications
Published: October 03, 2025

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Journal: EClinicalMedicine
Published: July 31, 2025

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.

Journal: MedComm
Published: July 16, 2025

Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China.

Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China.

Journal: Breast cancer (Dove Medical Press)
Published: June 11, 2025

Astrocyte involvement in brain metastasis: from biological mechanisms to therapeutic strategies.

Astrocyte involvement in brain metastasis: from biological mechanisms to therapeutic strategies.

Journal: Cancer metastasis reviews
Published: February 09, 2025

Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer.

Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer.

Journal: Genes and immunity
Published: December 15, 2024

Overcoming matrix barriers for enhanced immune infiltration using siRNA-coated metal-organic frameworks.

Overcoming matrix barriers for enhanced immune infiltration using siRNA-coated metal-organic frameworks.

Journal: Acta biomaterialia
Published: October 21, 2024

NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges.

NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges.

Journal: Life sciences
Published: October 31, 2023
Showing 1-12 of 24

Last Updated: 09/26/2026